Science Daily

New device designed to treat patients suffering from refractory angina

A new device, the Neovasc Reducer, is implanted in the coronary sinus vein using minimally invasive techniques. Placement of the device is performed using a procedure that is similar to implanting a ...
WGHP

Neovasc Announces FDA Approval of Planned COSIRA II Sub-studies and Single Arm Registry to Allow Inclusion of Additional Specified Patient Populations

VANCOUVER and MINNEAPOLIS, July 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced the United States Food and Drug ...
TCTMD

Narrowing Coronary Sinus May Provide Relief From Refractory Angina

A device that narrows the coronary sinus can reduce angina symptoms and improve quality of life in patients with refractory angina who are not candidates for revascularization, according to phase II ...
FOX8 Cleveland

Neovasc Announces Progress on COSIRA-II Clinical Trial

To accelerate recruitment of patients into the Trial, Neovasc is leveraging predictive machine learning technology from Komodo Health, to identify and engage healthcare practitioners (“HCP”) with ...
Healio

Coronary-Sinus Reducing Device Improved Symptoms, QOL in Patients with Angina

Please provide your email address to receive an email when new articles are posted on . In the phase 2 COSIRA trial, implantation of a coronary-sinus reducing device significantly improved symptoms ...